Analysts Expect ICU Medical, Incorporated (ICUI) to Post $1.47 EPS

Equities analysts expect ICU Medical, Incorporated (NASDAQ:ICUI) to post earnings of $1.47 per share for the current fiscal quarter, Zacks reports. Two analysts have made estimates for ICU Medical’s earnings, with the highest EPS estimate coming in at $1.61 and the lowest estimate coming in at $1.32. ICU Medical reported earnings per share of $1.12 during the same quarter last year, which suggests a positive year over year growth rate of 31.3%. The business is expected to report its next earnings results on Thursday, November 8th.

On average, analysts expect that ICU Medical will report full-year earnings of $8.48 per share for the current fiscal year, with EPS estimates ranging from $8.35 to $8.60. For the next year, analysts forecast that the business will post earnings of $9.95 per share, with EPS estimates ranging from $9.87 to $10.03. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that cover ICU Medical.

ICU Medical (NASDAQ:ICUI) last posted its earnings results on Thursday, August 9th. The medical instruments supplier reported $2.66 EPS for the quarter, topping the consensus estimate of $1.82 by $0.84. The firm had revenue of $360.46 million for the quarter, compared to analyst estimates of $337.60 million. ICU Medical had a return on equity of 12.78% and a net margin of 5.93%. ICU Medical’s revenue for the quarter was up 8.7% compared to the same quarter last year. During the same period last year, the company earned $0.76 earnings per share.

Several analysts recently commented on ICUI shares. ValuEngine lowered ICU Medical from a “buy” rating to a “hold” rating in a report on Tuesday, September 18th. TheStreet raised ICU Medical from a “c+” rating to a “b+” rating in a report on Monday, August 20th. Zacks Investment Research lowered ICU Medical from a “buy” rating to a “hold” rating in a report on Wednesday, July 11th. Finally, BidaskClub raised ICU Medical from a “hold” rating to a “buy” rating in a report on Friday, September 28th. Two research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. ICU Medical currently has a consensus rating of “Buy” and a consensus price target of $337.00.

In other ICU Medical news, VP Virginia Ruth Sanzone sold 787 shares of the firm’s stock in a transaction that occurred on Tuesday, August 28th. The stock was sold at an average price of $303.12, for a total value of $238,555.44. Following the sale, the vice president now directly owns 1,367 shares of the company’s stock, valued at $414,365.04. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Pfizer Inc sold 700,000 shares of the firm’s stock in a transaction that occurred on Monday, August 13th. The shares were sold at an average price of $284.35, for a total value of $199,045,000.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 711,920 shares of company stock worth $202,651,956. 12.50% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently modified their holdings of the business. Mackay Shields LLC acquired a new stake in ICU Medical in the second quarter valued at approximately $205,000. CIBC Asset Management Inc acquired a new stake in ICU Medical in the second quarter valued at approximately $209,000. LPL Financial LLC acquired a new stake in ICU Medical in the first quarter valued at approximately $218,000. Campbell & CO Investment Adviser LLC acquired a new stake in ICU Medical in the second quarter valued at approximately $230,000. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new stake in ICU Medical in the second quarter valued at approximately $235,000. 74.29% of the stock is currently owned by institutional investors.

ICU Medical stock traded up $1.01 during midday trading on Friday, hitting $273.65. 216,234 shares of the company were exchanged, compared to its average volume of 157,376. The firm has a market cap of $5.79 billion, a price-to-earnings ratio of 49.57 and a beta of 0.41. ICU Medical has a fifty-two week low of $180.45 and a fifty-two week high of $321.70.

About ICU Medical

ICU Medical, Inc develops, manufactures, and sells medical devices used in vascular therapy, critical care, and oncology applications worldwide. It offers infusion therapy products comprising a tube running from a bottle or plastic bag containing a solution to a catheter inserted in a patient's vein.

See Also: How is the discount rate different from the Federal Funds rate?

Get a free copy of the Zacks research report on ICU Medical (ICUI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply